Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Amgen Inc. AMGN: Absurd That This Stock Sells for 14x Earnings

February 14, 2025
Amgen Inc. (NASDAQ: AMGN) has been making waves in the pharmaceutical industry with its breakthrough drugs and innovative research. However, it seems that investors might be overlooking the potential of this stock. A recent analysis by industry experts at Stocks Prognosis reveals that Amgen is currently trading at just 14 times its earnings, which is considered to be significantly undervalued.

Amgen has a strong pipeline of blockbuster drugs and potential breakthrough treatments in various stages of development. With a focus on oncology, immunology, and cardiovascular diseases, the company is expected to continue its impressive growth trajectory. Investors should take note of this opportunity and consider adding Amgen to their portfolio.

Despite its promising outlook, some investors might be hesitant to buy Amgen shares due to concerns over its upcoming dividend. However, dividend investors should not be too quick to dismiss the company. Amgen has a solid track record of consistently increasing its dividend payout over the years, and its upcoming dividend is expected to follow suit.

To make an informed decision about the future movement of Amgen's stock, it is recommended to consult with professionals from Stocks Prognosis. Their expertise in analyzing market trends and predicting stock movements can provide valuable insights for investors looking to capitalize on the potential growth of Amgen Inc.
If you want to leave a comment, then you need Login or Register





Other data for AMGN

Related data

AMGNApril 22, 2025Amgen Inc. AMGN: Among the Innovative Healthcare Stocks to Watch in 2025  ~2 min.

Amgen Inc., a leading biotechnology company, is currently one of the most promising stocks in the healthcare sector....

AMGNMarch 20, 2025Hedge Funds Recommend Amgen Inc. AMGN as the Best Pharma Stock to Buy  ~1 min.

According to recent reports, hedge funds are strongly recommending Amgen Inc. (AMGN) as the best pharma stock to buy....

AMGNMarch 19, 2025Amgen Inc. AMGN: Cutting-Edge Biotech Company Dominates Stock Market  ~2 min.

Amgen Inc. (AMGN), renowned for its groundbreaking innovations in biotechnology, continues to make headlines as a leading player in the stock market....

AMGNMarch 17, 2025Amgen Inc. Continues to Impress Hedge Funds with Strong Performance  ~2 min.

Amgen Inc. (NASDAQ:AMGN) has emerged as the top choice for hedge funds looking to invest in the pharmaceutical sector....

AMGNMarch 16, 2025Amgen Inc. AMGN: Discover Why it's Among the Top Pharma Stocks to Buy  ~2 min.

Amgen Inc., a leading biotechnology company, has been gaining attention in the investment community due to its outstanding performance in the pharmaceutical sector....

AMGNMarch 7, 2025AMGEN INC. Hits Price Target Forecast with 19.78% Profit, as Predicted by QuantWave  ~2 min.

AMGEN INC. (AMGN) recently achieved the price target forecast set by QuantWave, resulting in a profit of 19.78% for investors who followed the prediction....

AMGNFebruary 27, 2025Amgen Inc. AMGN: A Promising Investment Opportunity in the Pharmaceutical Industry  ~2 min.

Amgen Inc. (AMGN), a leading biotechnology company, is regarded as one of the best investment options in the pharmaceutical sector, according to analysts at Yahoo Finance....

AMGNFebruary 26, 2025Amgen Inc. AMGN: Among the Cheap Pharmaceutical Stocks to Buy According to Analysts  ~1 min.

Analysts have identified Amgen Inc. (NASDAQ:AMGN) as one of the cheap pharmaceutical stocks to buy....

AMGNFebruary 20, 2025Amgen Inc. AMGN Reports Strong Earnings Amidst Growing Bull Case Theory  ~2 min.

Amgen Inc. (AMGN), a leading biotechnology company, has recently reported strong earnings, surpassing market expectations....

AMGNFebruary 10, 2025Amgen Inc AMGN Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions  ~1 min.

Amgen Inc (AMGN) recently held its Q4 2024 earnings call, where it highlighted robust revenue growth and strategic expansions. The company reported revenue surpassing estimates, reaching $9....

ABBVDecember 2, 2024AbbVie Inc. ABBV: A Promising Pharmaceutical Stock with Underrated Potential  ~2 min.

AbbVie Inc. (ABBV), a renowned pharmaceutical company, has been gaining attention as one of the most undervalued pot stocks in the market....

BMYJanuary 1, 2025Is Bristol-Myers Squibb Co. the Game-Changer in the Pharma Industry?  ~2 min.

Bristol-Myers Squibb Company (BMY), a renowned pharmaceutical giant, has been making significant strides in the industry....

BMYJanuary 22, 2025Bristol Myers Squibb Stock Shows Resilience in a Volatile Market  ~2 min.

Amidst a volatile stock market, Bristol Myers Squibb (BMY) has managed to maintain its stability and even show some gains....

VRTXJanuary 22, 2025Vertex Pharmaceuticals Incorporated VRTX Leading the Trend: What You Should Know  ~2 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been making waves in the stock market recently, attracting the attention of investors....

ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....